These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9379157)

  • 1. Response to claim of error by drug enforcement administration (DEA) chemist in calculating quantity of methadone synthesized from precursor chemicals.
    Hatcher AP; Ryan CR
    J Forensic Sci; 1997 Sep; 42(5):963. PubMed ID: 9379157
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug Enforcement Administration (DEA) chemists erred in calculating quantity of methadone that could be synthesized from precursor chemicals.
    Zedeck MS
    J Forensic Sci; 1997 Mar; 42(2):349-50. PubMed ID: 9068200
    [No Abstract]   [Full Text] [Related]  

  • 3. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 May; 68(84):23195-206. PubMed ID: 12725239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exemption of chemical mixtures. Final rule.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Mar; 72(47):10925-8. PubMed ID: 17450656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Special surveillance list of chemicals, products, materials and equipment used in the clandestine production of controlled substances or listed chemicals. Drug Enforcement Administration (DEA), Justice. Final notice.
    Fed Regist; 1999 May; 64(92):25910-2. PubMed ID: 10558537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB). Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jan; 70(2):291-4. PubMed ID: 15630794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Conference on Harmonisation; Guidance on Q8 Pharmaceutical Development; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 May; 71(98):29344-5. PubMed ID: 16749216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State-by-state pharmaceutical formulations?
    Frankel HH
    N Engl J Med; 1993 May; 328(20):1500-1. PubMed ID: 8479484
    [No Abstract]   [Full Text] [Related]  

  • 10. Sources of meth. U.S. Drug Enforcement Administration (DEA).
    GMHC Treat Issues; 2005; 19(7-8):14-5. PubMed ID: 16276574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(133):39611-4. PubMed ID: 18850676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revision of the requirements for live vaccine processing; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Mar; 73(46):12262-3. PubMed ID: 18464339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premarket notifications of new dietary ingredients--a ten-year review.
    McGuffin M; Young AL
    Food Drug Law J; 2004; 59(2):229-44. PubMed ID: 15318394
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs.
    Strong M
    Food Drug Law J; 1999; 54(3):463-87. PubMed ID: 11797710
    [No Abstract]   [Full Text] [Related]  

  • 16. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.
    Balakrishnan K; Grieve J; Tordoff J; Norris P; Reith D
    J Clin Pharmacol; 2006 Sep; 46(9):1038-43. PubMed ID: 16920899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Representation of chemical information in OASIS centralized 3D database for existing chemicals.
    Nikolov N; Grancharov V; Stoyanova G; Pavlov T; Mekenyan O
    J Chem Inf Model; 2006; 46(6):2537-51. PubMed ID: 17125194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of action by the Drug Enforcement Administration against physicians prescribing opioids for pain.
    Jung B; Reidenberg MM
    Pain Med; 2006; 7(4):353-7. PubMed ID: 16898947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditions for the use of methadone; intent to propose revisions to regulations and request for comments.
    Fed Regist; 1983 Sep; 48(178):41049-51. PubMed ID: 10317355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.